RxDoctor Payments Data

Chelsea Lee, DO

Dermatology · Wichita, KSNPI 1104122266

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.1% of the total across 368 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 28.1% of the total.

$6,598in general payments, 2019–2025

Across 368 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Regeneron Healthcare Solutions, Inc.$679
  • Novartis$555
  • Sanofi$544
  • Johnson & Johnson$520
  • Sun Pharmaceutical Industries Inc.$345
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,27295%
  • Education$3265%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,598 in reported general payments places this provider in the 85th percentile of 82 dermatology providers in Kansas.

See all dermatology providers in Kansas

Medicare billing

Part B allowed, 2024
$222,531
Medicare patients
908
Services billed
3,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa15$322,894
Dupixent PenDupilumab69$284,642
Clobetasol Propionate245$13,591
Metronidazole34$2,539
Betamethasone Dipropionate43$2,343
Ketoconazole125$2,206
Tacrolimus15$1,948
Doxycycline Hyclate77$1,879
Tretinoin19$1,415
Fluorouracil12$1,312
Ciclopirox34$1,139
Nystatin56$993
Clindamycin Phosphate25$967
Triamcinolone Acetonide47$739
Mupirocin81$541

Paid to pharmacies, not to this prescriber.

Other dermatology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →